APA (7th ed.) Citation

JS, K., CY, C., SC, C., YF, W., & CY, C. (2025). Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan. Current oncology (Toronto, Ont.), 32(1), . https://doi.org/10.3390/curroncol32010036

Chicago Style (17th ed.) Citation

JS, Kuo, Chang CY, Chang SC, Wei YF, and Chen CY. "Rebiopsy Enhances Survival with Afatinib Vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan." Current Oncology (Toronto, Ont.) 32, no. 1 (2025). https://doi.org/10.3390/curroncol32010036.

MLA (9th ed.) Citation

JS, Kuo, et al. "Rebiopsy Enhances Survival with Afatinib Vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan." Current Oncology (Toronto, Ont.), vol. 32, no. 1, 2025, https://doi.org/10.3390/curroncol32010036.